The only JAK inhibitor approved in the U.S. for the control of pruritus associated with allergic dermatitis in dogs six months of age and older RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, ...

If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and ...

MSD Animal Health has presented new clinical trial data showing its oral drug NUMELVI® (atinvicitinib) significantly reduces itching and skin inflammation in dogs with atopic and allergic dermatitis.

Canine atopic dermatitis is a common, chronic skin disease causing persistent itching, inflammation, and infections. Breakthrough therapies like targeted monoclonal antibodies and next-generation JAK ...

Dr. Meghan Herron serves as the senior director of behavior, research and education at Gigi’s, a shelter organization dedicated to improving the lives of shelter dogs. Prior to … You’d be surprised to ...

Humans aren’t the only ones who suffer from seasonal allergies. When the weather warms up in the spring, many dog owners notice their pets start to itch and scratch. Some dogs have severe reactions ...

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug ...

As allergic dermatitis progresses, quality of life in dogs and the human-animal bond can be significantly impacted due to physical discomfort, emotional distress, and interruptions in sleep and ...